Scientists at the University of Hong Kong have discovered that a newer class of diabetes drugs, called sodium-glucose cotransporter 2 inhibitors (SGLT2i), may offer additional benefits beyond lowering blood sugar for people with type 2 diabetes.
The research found that SGLT2i could reduce the risk of serious kidney and lung diseases, including end-stage renal disease (ESRD), obstructive airway disease (OAD), and pneumonia.
SGLT2i drugs are a relatively recent addition to the treatment options for type 2 diabetes. While their primary function is to lower blood sugar, studies in recent years have shown that they also protect the heart and kidneys in diabetes patients.
However, this study provides real-world evidence suggesting that SGLT2i may outperform an older class of diabetes drugs, called dipeptidyl peptidase-4 inhibitors (DPP4i), in safeguarding kidney and respiratory health.
The research analyzed data from over 30,000 patients with type 2 diabetes in Hong Kong. The findings revealed that SGLT2i were strongly associated with a lower risk of kidney diseases compared to DPP4i.
This reinforces previous studies that have highlighted the kidney-protective effects of SGLT2i, offering more evidence of their potential as a better treatment option.
In addition to kidney health, the study found that SGLT2i were linked to significantly reduced risks of lung diseases such as obstructive airway disease and pneumonia.
These findings are particularly noteworthy because diabetes patients are often at a higher risk of developing respiratory complications. The results suggest that SGLT2i may have a broader protective effect on overall health, beyond their role in managing blood sugar levels.
While these results are promising, the researchers recommend conducting clinical trials to further investigate the respiratory benefits of SGLT2i.
If confirmed, these drugs could represent a more comprehensive treatment option for people with type 2 diabetes, helping to manage their condition while also reducing the risks of complications in other organs.
Type 2 diabetes is a chronic condition that affects millions of people worldwide, increasing the risk of serious health problems like heart disease, kidney failure, and infections.
Treatments like SGLT2i are crucial not only for managing blood sugar but also for reducing these risks and improving overall health outcomes.
This study, led by Dr. Cheung Ching-lung and published in The Journal of Clinical Endocrinology & Metabolism and JAMA Network Open, highlights the growing importance of SGLT2i as a second-line treatment for type 2 diabetes.
As researchers continue to explore the potential benefits of these drugs, they could become a preferred choice for managing diabetes and protecting against complications.
For now, people with diabetes are encouraged to work closely with their healthcare providers to find the best treatment plan for their needs.
Alongside medication, maintaining a healthy diet and lifestyle remains key to managing the condition and preventing complications.
If you care about lungs, please read studies about a review of COPD-friendly foods for lung health, and can Vitamin C and E help fight lung cancer.
For more health information, please see recent studies about how diet influences lung health, and these vegetables could benefit your lung health.
Copyright © 2024 Knowridge Science Report. All rights reserved.
